Canakinumab + Placebo

Phase 3Completed

1 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Hereditary Periodic Fevers

Conditions

Hereditary Periodic Fevers

Trial Timeline

Jun 27, 2014 → Jul 4, 2017

NCT ID

NCT02059291

About Canakinumab + Placebo

Canakinumab + Placebo is a phase 3 stage product being developed by Novartis for Hereditary Periodic Fevers. The current trial status is completed. This product is registered under clinical trial identifier NCT02059291. Target conditions include Hereditary Periodic Fevers.

What happened to similar drugs?

3 of 20 similar drugs in Hereditary Periodic Fevers were approved

Approved (3) Terminated (0) Active (17)

✅Berinert, lyophilizate for IV application containing 500 IU C1-INH to be reconstituted with 10 mL water for injectionCSLApproved

✅GaradacimabCSLApproved

✅IdebenoneSanthera PharmaceuticalsApproved

🔄KVD900 600 mg + KVD900 300 mgKalVista PharmaceuticalsPhase 3

🔄Placebo + KVD900 600 mg + KVD900 300 mgKalVista PharmaceuticalsPhase 3

🔄KVD900 150 mg + KVD900 300 mg + KVD900 600 mgKalVista PharmaceuticalsPhase 3

🔄KVD900 600 mg + Drug: KVD900 300 mgKalVista PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (10)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05725343	Phase 3	Terminated	Feb 3, 2022	Sep 21, 2022	Lung Cancer
NCT04510493	Phase 3	Completed	Oct 23, 2020	Aug 17, 2021	Coronavirus Infection
NCT04362813	Phase 3	Completed	Apr 30, 2020	Dec 22, 2020	Cytokine Release Syndrome (CRS) in Patients With COVID-19-induced Pneumonia
NCT03447769	Phase 3	Terminated	Mar 16, 2018	Feb 7, 2023	Non-Small Cell Lung Cancer
NCT02059291	Phase 3	Completed	Jun 27, 2014	Jul 4, 2017	Hereditary Periodic Fevers
NCT01390350	Phase 2	Completed	Jul 1, 2011	May 1, 2018	Schnitzler Syndrome
NCT00889863	Phase 3	Completed	Jul 1, 2009	Sep 1, 2011	Systemic Juvenile Idiopathic Arthritis With Active Flare
NCT00886769	Phase 3	Terminated	Jul 1, 2009	Jan 1, 2011	Systemic Juvenile Idiopathic Arthritis
NCT00581945	Phase 1/2	Completed	Jan 1, 2007	May 1, 2010	Chronic Obstructive Pulmonary Disease
NCT00424346	Phase 2	Completed	Nov 1, 2006	Oct 1, 2009	Rheumatoid Arthritis

Competing Products

20 competing products in Hereditary Periodic Fevers

See all competitors

Product	Company	Stage	Hype Score
KVD900	KalVista Pharmaceuticals	Phase 2	29
KVD824 + Placebo to KVD824	KalVista Pharmaceuticals	Phase 1	23
KVD900 600 mg + KVD900 300 mg	KalVista Pharmaceuticals	Phase 3	38
Sebetralstat	KalVista Pharmaceuticals	Pre-clinical	20
KVD900 + Placebo to KVD900	KalVista Pharmaceuticals	Phase 1	23
Sebetralstat	KalVista Pharmaceuticals	Pre-clinical	24
Placebo + KVD900 600 mg + KVD900 300 mg	KalVista Pharmaceuticals	Phase 3	34
KVD824 Prototype 1 modified-release tablet + KVD824 Prototype 2 modified-release tablet + KVD824 Immediate-Release Capsule + Placebo to KVD824 Prototype 1 + KVD824 Prototype 3 modified-release tablet	KalVista Pharmaceuticals	Phase 1	23
KVD900 150 mg + KVD900 300 mg + KVD900 600 mg	KalVista Pharmaceuticals	Phase 3	34
KVD824 + Placebo to KVD824	KalVista Pharmaceuticals	Phase 2	21
KVD900 600 mg + Drug: KVD900 300 mg	KalVista Pharmaceuticals	Phase 3	38
Deferasirox FCT	Novartis	Phase 2	27
Ilaris	Novartis	Pre-clinical	33
Standard of Care for Haemophilia A	Roche	Pre-clinical	26
Emicizumab	Roche	Phase 3	40
Tafamidis	Pfizer	Pre-clinical	26
tafamidis	Pfizer	Pre-clinical	26
Nitisinone	Swedish Orphan Biovitrum	Pre-clinical	26
Nitisinone	Swedish Orphan Biovitrum	Phase 1	29
Nitisinone	Swedish Orphan Biovitrum	Pre-clinical	18